EFFICACY OF TRIMETAZIDINE IN ELDERLY PATIENTS WITH CORONARY HEART DISEASE AND HEART FAILURE
Objective To observe the efficacy of trimetazidine in the treatment of elderly patients with coronary heart disease and heart failure and its effect on heart function,and to explore its clinical value.Methods A total of 114 elderly patients with coronary heart disease and heart failure were randomly divided into observation group and control group with 57 cases in each group.The patients in both groups were given conventional treatment.Meanwhile,the patients in the observation group were additionally administered trimetazidine.One course of treatment fasted 12 weeks,and the both groups were treated for 2 courses.The clinical efficacy and the changes in cardiac function classification and left ventricular function were compared between these two groups.Results After treatment,both groups had significantly reduced left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD) and significantly increased left ventricular ejection fraction (LVEF) and peak early diastolic blood flow velocity/peak late diastolic blood flow velocity ratio (E/A) (t=1.957-7.139,P＜0.05).Furthermore,compared with the control group,the observation group had significantly greater reductions in LVEDD and LVESD and significantly greater increases in LVEF and E/A (t=3.086 5.917,P＜0.05).After treatment,the N-terminal brain natriuretic peptide (NTproBNP) level was significantly reduced in both groups (t =13.525,16.391;P＜0.05),and the level was significantly lower in the observation group than in the control group (t 5.087,P＜0.05).The heart function classifications were also significantly improved after treatment in these two groups (Z 6.489,4.152;P＜0.05),and the overall improvement in heart function was more obvious in the observation group than in the control group (Z=3.427,P＜0.05).The overall response rate was significantly higher in the observation group than in the control group (87.7％ vs 64.9％,x2 =6.582,P＜0.05).Conclusion Trimetazidine can significantly reduce the level of NT-proBNP and promote the recovery of cardiac function in elderly patients with coronary heart disease and heart failure,which has great significance for improving the clinical symptoms and prognosis of these patients.
trimetazidineagedcoronary diseaseheart failureheart function teststreatment outcome
NETL
NSTL
万方数据
维普
